AN2 Therapeutics (ANTX) Stock Analysis

What AN2 Therapeutics does

AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.

Key metrics

ETFs linked to ANTX

Broad-market and Healthcare sector ETFs an investor holding AN2 Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ANTX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for AN2 Therapeutics?

AN2 Therapeutics trades under the ticker ANTX on NASDAQ.

Which exchange is ANTX listed on?

ANTX is listed on NASDAQ.

What sector does AN2 Therapeutics operate in?

AN2 Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ANTX in a portfolio?

PortView shows ANTX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.